-
Something wrong with this record ?
Czech TAVI Registry - rationale and design
Petr Kala, Milan Blaha
Language English Country Czech Republic
- Keywords
- nemocní s vysokým operačním rizikem, registr, transkatetrová implantace aortální chlopně (TAVI),
- MeSH
- Directories as Topic MeSH
- Aortic Valve Stenosis therapy MeSH
- Heart Valve Prosthesis Implantation contraindications methods adverse effects MeSH
- Databases as Topic MeSH
- Humans MeSH
- Heart Valve Prosthesis statistics & numerical data MeSH
- Cardiac Catheterization history methods MeSH
- Check Tag
- Humans MeSH
- Geographicals
- Czech Republic MeSH
Aortic stenosis is the most common type of valve disease in the adults. Until recently its treatment was an exclusive domain of cardiac surgery. At the same time the aortic valve replacement (SAVR) was not indicated in about 1/3 of the patients, though the prognosis of conservatively treated patients is very unfavourable with one-year mortality rate of 50%. These facts were the main reasons for starting a new interventional era of the aortic valve disease therapy in 2002 and from 2007 two types of valves fixed in stents have been commercially available. In the early phase the transcatheter aortic valve implantation (TAVI) was used just in patients with contraindication to SAVR or with high perioperative risk after surgery. Before applying this therapy to less risky patients some problems have to be solved: 1. clinical impact of the relatively high rate of paravalvular leaks and 2. long-term function of the implanted valve in follow-up exceeding 5 years. In the Czech Republic the first TAVI was performed in Prague, IKEM in December 2008. During a short period of time the TAVI programme was initiated also in other complex cardiovascular centres in Hradec Kralove, Brno, Prague—FN Kralovske Vinohrady and Trinec. Including the later starting centres (Usti n. Labem, Olomouc, Ceske Budejovice and other three centres in Prague—Nemocnice na Homolce, FN Motol and VFN) there is a total of 11 centres providing the TAVI at present. All centres except one (FN Motol) are part of the Czech TAVI Registry that was developed with the support of the Czech Society of Cardiology and started on 1 September, 2010. In general and more theoretically there are two parts of the Registry: 1. “Retrospective” including all the TAVI procedures from the beginning of the TAVI programme in the Czech Republic that was terminated on June 30, 2011 and 2. “Prospective” that has been following. Institute of Biostatistics and Analyses of Masaryk University takes care of the online and anonymized database. The results of the national Czech TAVI Registry should help to answer the clinical relevant questions mentioned above.
Obsahuje tabulky
Bibliography, etc.Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12021219
- 003
- CZ-PrNML
- 005
- 20170111131756.0
- 007
- ta
- 008
- 120731s2012 xr f 000 0eng||
- 009
- AR
- 024 7_
- $2 doi $a 10.1016/j.crvasa.2012.05.003
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng $b cze
- 044 __
- $a xr
- 100 1_
- $a Kala, Petr, $d 1965- $7 xx0043092 $u Department of Internal Medicine and Cardiology, Masaryk University and University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic
- 245 10
- $a Czech TAVI Registry - rationale and design / $c Petr Kala, Milan Blaha
- 500 __
- $a Obsahuje tabulky
- 504 __
- $a Literatura $b 12
- 520 9_
- $a Aortic stenosis is the most common type of valve disease in the adults. Until recently its treatment was an exclusive domain of cardiac surgery. At the same time the aortic valve replacement (SAVR) was not indicated in about 1/3 of the patients, though the prognosis of conservatively treated patients is very unfavourable with one-year mortality rate of 50%. These facts were the main reasons for starting a new interventional era of the aortic valve disease therapy in 2002 and from 2007 two types of valves fixed in stents have been commercially available. In the early phase the transcatheter aortic valve implantation (TAVI) was used just in patients with contraindication to SAVR or with high perioperative risk after surgery. Before applying this therapy to less risky patients some problems have to be solved: 1. clinical impact of the relatively high rate of paravalvular leaks and 2. long-term function of the implanted valve in follow-up exceeding 5 years. In the Czech Republic the first TAVI was performed in Prague, IKEM in December 2008. During a short period of time the TAVI programme was initiated also in other complex cardiovascular centres in Hradec Kralove, Brno, Prague—FN Kralovske Vinohrady and Trinec. Including the later starting centres (Usti n. Labem, Olomouc, Ceske Budejovice and other three centres in Prague—Nemocnice na Homolce, FN Motol and VFN) there is a total of 11 centres providing the TAVI at present. All centres except one (FN Motol) are part of the Czech TAVI Registry that was developed with the support of the Czech Society of Cardiology and started on 1 September, 2010. In general and more theoretically there are two parts of the Registry: 1. “Retrospective” including all the TAVI procedures from the beginning of the TAVI programme in the Czech Republic that was terminated on June 30, 2011 and 2. “Prospective” that has been following. Institute of Biostatistics and Analyses of Masaryk University takes care of the online and anonymized database. The results of the national Czech TAVI Registry should help to answer the clinical relevant questions mentioned above.
- 650 _2
- $a databáze jako téma $7 D019992
- 650 _2
- $a srdeční katetrizace $x dějiny $x metody $7 D006328
- 650 _2
- $a aortální stenóza $x terapie $7 D001024
- 650 _2
- $a chirurgická náhrada chlopně $x kontraindikace $x metody $x škodlivé účinky $7 D019918
- 650 _2
- $a srdeční chlopně umělé $x statistika a číselné údaje $7 D006350
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a adresáře jako téma $7 D004181
- 651 _2
- $a Česká republika $7 D018153
- 653 00
- $a nemocní s vysokým operačním rizikem
- 653 00
- $a registr
- 653 00
- $a transkatetrová implantace aortální chlopně (TAVI)
- 700 1_
- $a Blaha, Milan $7 xx0209712 $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
- 773 0_
- $t Cor et vasa $x 0010-8650 $g Roč. 54, č. 5-6 [3] (2012), s. 230-234 (e e143-e150) $w MED00010972
- 856 41
- $u https://e-coretvasa.cz/pdfs/cor/2012/05/20.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 2980 $c 438 $y 2 $z 0
- 990 __
- $a 20120731115810 $b ABA008
- 991 __
- $a 20170111131854 $b ABA008
- 999 __
- $a ok $b bmc $g 915428 $s 778501
- BAS __
- $a 3
- BMC __
- $a 2012 $b 54 $c 5-6 $g 3 $d 230-234 $f e143-e150 $i 0010-8650 $m Cor et Vasa (Brno) $n Cor Vasa (Brno Print) $x MED00010972
- LZP __
- $a 2012-33/dkjč